BridgeMD
New treatment option for Coronary Artery Disease
Official title CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD
ClinicalTrials.gov ID: NCT06820970
What this study is testing
- What it's testing
- The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can reduce cardiovascular adverse events in patients with incomplete revascularization of coronary artery disease.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 1) Age ≥18 years old
- 2) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least...
- 3) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);
You likely can't join if
- Age \< 18 years old
- Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \< 30%
- Creatinine clearance \<15 mL/min (or eGFR \< 15 mL/min/1.73m²), or requires dialysis
- Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.
- Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete...
- Poorly controlled hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg)
See the full eligibility criteria
- 1) Age ≥18 years old
- 2) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than...
- 3) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);
- Age \< 18 years old
- Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \< 30%
- Creatinine clearance \<15 mL/min (or eGFR \< 15 mL/min/1.73m²), or requires dialysis
- Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.
- Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates...
- Poorly controlled hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg)
- Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal
- Unexplained CK \> 5 times the upper limit of normal, or elevated CK due to known muscle disease
- Planned or anticipated cardiac surgery or revascularization before randomization
- History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
- Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis
- Hearing impairment, unable to undergo mindfulness therapy
- Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug
- Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)
- Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study
- History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)
- Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine...
- As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.
The study team makes the final eligibility decision.
Where it's taking place
- Zhengzhou, Henan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zhengzhou, Henan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.